Market Place
Sourcing Support
DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions
26 Oct 2023 //
BUSINESSWIRE
Revance`s Botox rival gets FDA approval for painful neck muscle condition
15 Aug 2023 //
REUTERS
Revance to Present Data on DAXXIFY for Injection for the Treatment of Cervical Dystonia
23 Feb 2023 //
BUSINESSWIRE
Revance to Present Data on the Efficacy & Safety of DAXXIFY for ASDS Meeting
10 Oct 2022 //
BUSINESSWIRE
Revance Announces Publications Highlighting the Efficacy Profile of DAXXIFY
19 Sep 2022 //
BUSINESSWIRE
Brand Institute Partners on Brand Name and Nonproprietary
12 Sep 2022 //
PRNEWSWIRE
U.S. FDA approves Revance`s Botox rival
09 Sep 2022 //
HEALTH ET
Revance Announces FDA Approval of DAXXIFY for Injection
08 Sep 2022 //
BUSINESSWIRE
Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
09 Aug 2022 //
BUSINESSWIRE
Revance Resubmits BLA for DaxibotulinumtoxinA for Injection for Glabellar Lines
08 Mar 2022 //
BUSINESSWIRE
Following CRL, Revance says it`s clear on instructions for resubmitting BLA
19 Jan 2022 //
ENDPTS
Revance Receives Clarity on Path to Resubmission of BLA for DaxibotulinumtoxinA
18 Jan 2022 //
BUSINESSWIRE
Revance Reports Third Quarter 2021 Financial Results, Provides Corporate Update
09 Nov 2021 //
BUSINESSWIRE
Analysts like Revance`s chances in AbbVie Botox patent suit
12 Oct 2021 //
FIERCEPHARMA
AbbVie sues Botox rival Revance for patent infringement
06 Oct 2021 //
FIERCEPHARMA
Revance Announces Positive Topline Phase 2 Data Supporting DaxibotulinumtoxinA
22 Feb 2021 //
BUSINESSWIRE
FDA Defers Approval of DaxibotulinumtoxinA for Injection in Glabellar Lines
25 Nov 2020 //
BUSINESSWIRE
Revance Announces Results of Phase 2 Trial of DaxibotulinumtoxinA for inj
09 Nov 2020 //
BUSINESSWIRE
Revance to Present Extracts at ASDS Virtual Annual Meeting
06 Oct 2020 //
BUSINESSWIRE
Revance Announces Last Patient Enrolled in Modified JUNIPER Phase 2 Upper Limb
30 Jun 2020 //
BUSINESSWIRE
Revance Announces Publication of Pooled Results from Phase 3 Trials
05 Dec 2019 //
BUSINESS WIRE
Revance Submits Biologics License Application (BLA) to the FDA for DAXI
25 Nov 2019 //
BUSINESS WIRE
Revance Completes Enrollment in ASPEN-1 Ph3 Pivotal Trial for Cervical Dystonia
04 Nov 2019 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.